Previous 10 | Next 10 |
Omeros (OMER) is nearing the launch of its potential blockbuster, Narsoplimab. The drug's first target is HSCT-TMA. The company expects to receive FDA approval in late-2020. This document is intended to review the competitive landscape of Narsoplimab in HSCT-TMA. This is in no way a thorou...
Topline data from an initial six-subject cohort in an open-label, single-arm Phase 2 clinical trial evaluating Regeneron Pharmaceuticals' (NASDAQ: REGN ) pozelimab (REGN3918) in patients with paroxysmal nocturnal hemoglobinuria (PNH) showed a positive effect. More news on: Regene...
ASLAN Pharmaceuticals (NASDAQ: ASLN ) +85% on positive ASLAN004 data. More news on: ASLAN Pharmaceuticals Limited, Akari Therapeutics, Plc, Evofem Biosciences, Inc., Stocks on the move, Read more ...
Thinly traded nano cap Akari Therapeutics (NASDAQ: AKTX ) is up 28% premarket on robust volume on the heels of its design of a two-part Phase 3 clinical trial evaluating Coversin (nomacopan) in pediatric patients hematopoietic stem cell transplant-related thrombotic microangiopat...
Update on Paroxysmal Nocturnal Hemoglobinuria (PNH) Long Term Safety Study Shows 100% Transfusion Independence Two-part pivotal Phase III study of nomacopan in pediatric patients with HSCT-TMA based on guidance from End-of-Phase II meeting with U.S. Food and Drug Administration (FD...
Akari Therapeutics (NASDAQ: AKTX ): Q3 GAAP EPS of $0.00. More news on: Akari Therapeutics, Plc, Earnings news and commentary, Healthcare stocks news, , Read more ...
- New data demonstrate dual role of C5 and LTB4 in both bullous pemphigoid (BP) and atopic keratoconjunctivitis (AKC). There are no U.S. Food and Drug Administration (FDA)-approved treatments for either disease. - Clinical progress across our target conditions Phase I...
Biopsy tissue expresses the complement C5a receptor 1 and the leukotriene LTB4 receptor BLT1 on and within the surface of the eye, a previously unreported finding These new findings suggest that inhibition of both LTB4 and C5 by nomacopan may provide therapeutic effect by reducing bot...
Akari Therapeutics ( AKTX -8.1% ) is down in early trade on the heels of the release of data from an ongoing Phase 2 clinical trial evaluating Coversin (nomacopan) in patients with a rare skin-blistering disorder called bullous pemphigoid (BP). The results are being presented...
PG&E (NYSE: PCG ) -29% on bankruptcy judge decision clearing way for Elliott plan. More news on: PG&E Corporation, Forescout Technologies, Inc., HEXO Corp., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Akari Therapeutics Plc Company Name:
AKTX Stock Symbol:
NASDAQ Market:
BOSTON and LONDON, April 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the company will present new pre-clinical data on investigational long-acting PAS-nomacopan...
BOSTON and LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the full year 2023 as well as recent company highlights. ...
NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potenti...